Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-06-14
2011-06-14
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S242000, C544S278000, C544S281000, C514S247000
Reexamination Certificate
active
07960382
ABSTRACT:
Novel compounds and their uses are disclosed herein.
REFERENCES:
patent: 3890319 (1975-06-01), Danielewicz
patent: 4195085 (1980-03-01), Stone
patent: 4861760 (1989-08-01), Mazuel
patent: 5021410 (1991-06-01), Burke
patent: 5856329 (1999-01-01), Wheeler
patent: 6174524 (2001-01-01), Bawa
patent: 6194415 (2001-02-01), Wheeler
patent: 6248741 (2001-06-01), Wheeler
patent: 6316441 (2001-11-01), Dean
patent: 6410045 (2002-06-01), Schultz
patent: 6441047 (2002-08-01), DeSantis
patent: 7534795 (2009-05-01), Ruckmick et al.
patent: WO 03/088973 (2003-10-01), None
patent: WO 2007/050615 (2007-05-01), None
Arici et al., “A short term study of the additive effect of Timolol and Brimonidine on intraocular pressure”, Eye, 2002, vol. 16, No. 1, pp. 39-43.
Goni, “12-week study comparing the fixed combination of brimonidine and Timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension”, European Journal of Ophthalmology, vol. 15, No. 5, 2005, pp. 581-590.
Hommer, A.B., et al., Efficacy and Safety of Unoprostone, Dorzolamide, and Brimonidine and Adjunctive Therapy to Timolol in Patients with primary open-angle glaucoma and ocular hypertension, Investigative Ophthalmology & Visual Science, vol. 42, No. 4, Supp. Mar. 15, 2001, p. S554. ABS.
Hoyng, P.F., et al., Pharmacological Therapy of glaucoma, Drugs, vol. 59, No. 3, Mar. 2000 pp. 411-434.
Jackson, et al. “Cardiovascular effects of Timolol, Brimonidine and Brimonidine/Timolol in combination”, IOVS, 2001:42(4):S418 ABS 2250.
Larsson, “Aqueous humor flow in normal human eyes treated with Brimonidine and timolol, alone and in combination”. IOVS, 1999, vol. 40, No. 4, pp. S515.
Larsson, L.I. Aqueous humor flow in normal human eyes treated with Brimonidine and Timolol, alone and in combination, Arch Ophthalmol. vol. 119, Apr. 2001, p. 492-495.
Sall, et al., A Comparison of the Ocular Hypotensive Effect of Dorzolaminde Hydrochloride/Timolol Maleate to that of the Concomitant Therapy with Brimonidine Tartate and Timolol Maleate in Patients with Ocular Hypertension or Primary open-Angle Glaucoma. IOVS, 2001, vol. 42, No. 4, pp. S822, ABS 4412.
Schuman, J.S., Clinical experience with Brimonidine 0.2% and Timolol 0.5% in glaucoma and ocular hypertension, Survey of Ophthalmology, vol. 40, Supp. 1, Nov. 1996, p. s27-s37.
Stewart et al., “Cardiovascular effects of Timolol maleate, Brimonidine or Brimonidine/Timolol maleate in comcomitant therapy”, Acta Ophthalmologica Scandinavia, 2002, 80(3), 277-281.
Stewart, W.C., Perspectives in the medical treatment of glaucoma, Current Opinion in ophthalmology, vol. 10, No. 2, Apr. 1999, pp. 99-108.
Wang, R.F., et al., Comparison of the ocular hypotensive effect of Brimonidine, Dorzolamide, lantanoprost, or artificial tears added to Timolol in glaucomatous monkey eyes, J. of Glaucoma 9: 458-462.
Yuksel et al., “The short-term effect of adding Brimonidine 0.2% to Timolol treatment in patients with open-angle glaucoma”, Ophthalmologica, 1999, 213(4), 228-233.
Abreo Milton J.
Cain Robert
Fahid Massoud
Johnson Brent A.
Ruckmick Stephen
Allergan Inc.
Ene Doina G.
Forrestal Kevin J.
Shameem Golam M
Wurst John E.
LandOfFree
Compounds and their use related to compositions for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and their use related to compositions for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and their use related to compositions for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2635706